12 May 2015 07:01
12 May 2015
Motif Bio Plc
("Motif", the "Company" or the "Group")
MOTIF SELECTED TO PRESENT AT WORLD'S LARGEST BIOTECH EVENT
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria, announced today that the Company has been selected to present at the 2015 BIO International Convention, the leading global event for the Biotechnology sector.
BIO International is the world's largest biotech meeting, regularly attracting 15,000 of the world's most powerful biotechnology and pharmaceutical players from 65 countries, offering unparalleled business partnering, education and networking. The convention is to be held in the Pennsylvania Convention Centre, Philadelphia, Pennsylvania, USA, on 15-18 June 2015.
Enquiries:
Motif Bio plc Graham Lumsden (Chief Executive Officer) Robert Bertoldi (Chief Financial Officer) www.motifbio.com
| info@motifbio.com |
Plumtree Capital (FINANCIAL ADVISER) Stephen Austin
| +44 (0) 207 183 5860 |
Cairn Financial Advisers (NOMINATED ADVISER) | +44 (0) 20 7148 7900 |
Tony Rawlinson/Carolyn Sansom
| |
Northland Capital Partners Limited (BROKER) | +44 (0) 207 382 1100 |
Gerry Beaney/David Hignell | |
John Howes/Mark Treharne (Broking)
| |
Yellow Jersey PR Limited (LONDON IR) Dominic Barretto/Philip Ranger/Fiona Walker
MC Services (EUROPEAN PR) Raimund Gabriel/Shaun Brown | +44 (0) 7768 537 739
+49 (0) 89 210 2280 |
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.